TheSchall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit againstVerve Therapeutics, Inc. (“Verve” or “the Company”) (NASDAQ: VERV) forviolations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg
Investors who purchased the Company’s securities betweenAugust 9, 2022, and April 1, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before October 28, 2024.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website atwww.schallfirm.com, or by email atbschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Verve failed to disclose the circumstances under which its Heart-1 Phase 1b clinical trial (the “Heart-1 Trial”) of VERVE-101 would be halted. The Company overstated the benefits of its proprietary lipid nanoparticle (LNP) delivery system. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Verve, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law FirmBrian Schall, Esq.,www.schallfirm.comOffice: 310-301-3335info@schallfirm.com
https://c212.net/c/img/favicon.png?sn=LA14051&sd=2024-09-25
View original content to download multimedia:https://www.prnewswire.com/news-releases/verv-investors-have-opportunity-to-lead-verve-therapeutics-inc-securities-fraud-lawsuit-filed-by-the-schall-law-firm-302256631.html
SOURCE The Schall Law Firm
https://rt.newswire.ca/rt.gif?NewsItemId=LA14051&Transmission_Id=202409250830PR_NEWS_USPR_____LA14051&DateId=20240925
COMTEX_458151050/1005/2024-09-25T08:30:34